Knight Initiative for Brain Resilience

The first Monday of each month, the Knight Initiative for Brain Resilience will host monthly seminars to bring together awardees, affiliated professors and students for a series of 'lab meeting' styled talks. Two speakers will discuss their brain resilience research, experiences in the field, and answer questions about their work.

To support our researchers' participation in this open science ‘lab-meeting style’ exchange of ideas, these seminars are not streamed/recorded and are only open to members of the Stanford community. 

The first Monday of each month, the Knight Initiative for Brain Resilience will host monthly seminars to bring together awardees, affiliated professors and students for a series of 'lab meeting' styled talks. Two speakers will discuss their brain resilience research, experiences in the field, and answer questions about their work.

To support our researchers' participation in this open science ‘lab-meeting style’ exchange of ideas, these seminars are not streamed/recorded and are only open to members of the Stanford community. 

The drug, Kisunla, made by Eli Lilly, is the latest in a new class of treatments that could modestly slow cognitive decline in initial stages of the disease, but which also carry safety risks according to Knight Initiative for Brain Resilience affiliate Mike Greicius and others.

The Knight Initiative's Year-End Symposium and Research Showcase featured a wide range of promising new approaches to understanding brain aging, resilience, and neurodegeneration.

Donanemab slows symptoms of Alzheimer's, but its long-term effects are uncertain. Kathleen Poston, a Knight Initiative steering committee member, emphasizes the need for scientists to obtain data to extrapolate these findings to everyone with AD.

Most Parkinson’s disease patients struggle with speech problems. New research by Stanford Medicine scientists uncovers the brain connections that could be essential to preserving speech.

Wu Tsai Neuro and Knight Initiative for Brain Resilience affiliate, Michael Greicius, and others share their expertise on the limitations of the Alzheimer's drug Leqembi.

Why do our brains get worse at learning as we get older, and what can we do about it? Institute affiliate Carla Shatz discusses our brain's capacity for change on this podcast episode.

Join us for the inaugural ‘Knight/Glenn Aging & Resilience Seminar Series’ featuring Dr. Ursula Jakob, from the University of Michigan Medical School. Dr. Jakob will discuss "Early life ROS as modulators of lifespan and age-associated diseases”, hosted by Knight Initiative Awardee, Dr. Judith Frydman. 

This collaborative seminar, a joint effort of the Knight Initiative for Brain Resilience and the Paul F. Glenn Center for Biology of Aging Research, marks the beginning of our 2024-2025 Seminar Series, comprising four engaging events.

Knight Initiative for Brain Resilience Fall Symposium

The Knight Initiative for Brain Resilience at Stanford invites the community to a symposium highlighting recent progress in Huntington’s Disease research. In addition to talks, the event will include a clinical presentation and a poster session featuring recent findings by researchers supported by the Knight Initiative awards, fellowships, and Stanford affiliates of all career stages.

Join us for the science and celebratory social after the symposium!

Symposium: Progress in Huntington's Disease